Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ragweed pollen extract is a biological product derived from the pollen of *Ambrosia artemisiifolia*, commonly known as ragweed. It is primarily utilized in the study, diagnosis, and treatment of allergic diseases such as allergic rhinitis, asthma, and ocular allergy. The extract contains various allergenic proteins, including the major allergen Amb a 1, as well as Amb a 8, Amb a 9, Amb a 10, and profilin. It is known to elicit robust allergic responses by stimulating IgE production, inducing Th2-type airway inflammation, activating the NLRP3 inflammasome, and promoting the recruitment of inflammatory cells like eosinophils and neutrophils. Its effects are mediated, in part, through pathways involving Toll-like receptor 4 (TLR4) and Myeloid differentiation protein 2 (MD2), and it can induce oxidative stress and reactive oxygen species (ROS) production. Pollen-derived adenosine has also been identified as a critical cofactor in its allergenicity. The extract is a key component in diagnostic methods such as skin prick tests and is administered in allergen-specific immunotherapy (AIT) to modify the disease course of ragweed allergy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ragweed pollen extract.